Recursion Co News Today

Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second...

Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readoutsDelivered against...

/PRNewswire/ -- Recursion (NASDAQ: RXRX) today announced the release of its inaugural Environmental, Social and Governance (ESG) Report, highlighting the...

Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal...

/PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery,...

/PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological...

Share this article SALT LAKE CITY, March 1, 2021 /PRNewswire/ -- Recursion, a digital biology company industrializing drug discovery, today announced the appointment of R. Martin Chavez as Chairman of its Board of Directors. Dr. Chavez, who joined Recursions Board of Directors in 2020, will serve as the companys first independent Chairman. In this role, Dr. Chavez will oversee the organizations goals with regard to investor relations and apply his career-long innovation expertise to support Re...